Abstract

Single crystals of salmeterol xinafoate (form I), prepared from slow cooled supersaturated propan-2-ol solutions, crystallize in a triclinic P1¯ symmetry with 2 closely related independent salt pairs within the asymmetric unit, with an approximately double-unit cell volume compared with the previously published crystal structure. Synthonic analysis of the bulk intermolecular packing confirms the similarity in packing energetics between the 2 salt pairs. The strongest synthons, as expected, are dominated by coulombic interactions. Morphologic prediction reveals a plate-like morphology, dominated by the {001}, {010}, and {100} surfaces, consistent with experimentally grown crystals. Although surface chemistry of the slow-growing {001} face comprises large sterically hindering phenyl groups, although weaker coulombic interactions still prevail from the alcohol group present on the phenyl and hydroxymethyl groups. The surface chemistry of the faster growing {010} and {100} faces are dominated by the significantly stronger cation/anion interactions occurring between the carboxylate and protonated secondary ammonium ion groups. The importance of understanding the cohesive and adhesive nature of the crystal surfaces of an active pharmaceutical ingredient, with respect to their interaction with other active pharmaceutical ingredient crystals and how that may affect formulation design, is highlighted.

Highlights

  • IntroductionSalmeterol xinafoate (2-(hydroxymethyl)-4-[1-hdyroxy-2-[6-(4(phenylbutoxy) hexylamino] ethyl] phenol, 1-hydroxynaphthalene-

  • Salmeterol xinafoate (2-(hydroxymethyl)-4-[1-hdyroxy-2-[6-(4(phenylbutoxy) hexylamino] ethyl] phenol, 1-hydroxynaphthalene-2-carboxylic acid (SX)) is a long-acting b2-adrenoceptor agonist

  • The re-crystallization and characterization of salmeterol xinafoate form I have been carried out revealing a crystal structure that contains 2 crystallographically independent salt pairs, associated with conformational differences between the 2 salmeterol ions

Read more

Summary

Introduction

Salmeterol xinafoate (2-(hydroxymethyl)-4-[1-hdyroxy-2-[6-(4(phenylbutoxy) hexylamino] ethyl] phenol, 1-hydroxynaphthalene-. 2-carboxylic acid (SX)) is a long-acting b2-adrenoceptor agonist. It is commonly used on its own, or in combination with fluticasone propionate, for treating asthma. This material is present as the active pharmaceutical ingredient (API) in Serevent Diskus© (GlaxoSmithKline). SX is a salt that can exist in 2 known crystalline polymorphic forms that exhibit an enantiotropic relationship, with form I being the stable polymorph[1] and form II being the metastable polymorph at ambient conditions.[2,3] Thermal studies of salmeterol

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.